Skip to content

Diagnostic Agreement of iFR and QFR.

DETErmining the funCTional Significance of Intermediate Stenoses in isCHEMIc heArt Disease (DETECT ISCHEMIA): Diagnostic Agreement of iFR and QFR.

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03420131
Acronym
DETECTISCHEMIA
Enrollment
250
Registered
2018-02-05
Start date
2017-07-18
Completion date
2018-10-01
Last updated
2018-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease, Fractional Flow Reserve, Myocardial

Keywords

instantaneous Flow Ratio, Quantitative Flow Ratio, Fractional Flow Reserve

Brief summary

A Prospective, observational, single center diagnostic study to investigate the the diagnostic agreement between QFR and the pressure wire-based iFR in a real world setting.

Detailed description

During coronary angiography, intermediate stenoses can not be adequately assessed by visual assessment alone. It is necessary to evaluate the functional significance to guide their treatment. Fractional Flow Reserve (FFR) is the current gold standard for determining this functional significance but its adoption in clinical practice remains low. The instantaneous wave-free ratio (iFR) is an alternative way to determine the flow-limiting characteristics of a coronary stenosis with a pressure wire but without the need to induce hyperemia. Large randomised trials have confirmed the non-inferiority of iFR in respect to FFR in terms of outcome. Quantitative Flow Ratio (QFR) is another new method for evaluating the functional significance of coronary stenosis It is a software-based analysis of conventional angiographic images to estimate the pressure drop caused by a coronary stenosis. The diagnostic agreement with FFR seemed promising in the FAVOR Pilot Study and a larger trial is enrolling for confirmation. A stepwise approach of QFR and iFR could make the functional assessment of intermediate stenoses more practical and cost-effective. However before being used as a combination in daily practice, QFR has to be validated in respect to iFR. The primary objective of the trial is to investigate the diagnostic agreement between QFR and the pressure wire-based iFR in a real world setting

Interventions

DIAGNOSTIC_TESTQFR and iFR

iFR® (CE-Marked) is a pressure-derived, hyperemia-free index for the assessment of coronary stenosis relevance. This option consists of an FFR-iFR® specific patient interface module (PIM-FFR) which can be connected to the Volcano system - VOLCANO s5 or s5i™ platform equipped with iFR® option. QFR® (CE-Marked) is an angio-based FFR estimation using the analytical Software QAngio XA 3D from Medis medical imaging B.V., The Netherland

Sponsors

Contilia Clinical Research Institute
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age \> 18 with symptoms of myocardial ischemia and angina or angina equivalent (chest pain, abnormal stress testing, abnormal noninvasive testing) * Patients witch semi recent (\>3 days) acute coronary syndromes can be included but only for the non-culprit vessels and outside of primary intervention during acute myocardial infarction. * Willing to participate and able to understand, read and sign the informed consent document before the planned procedure * Eligible for coronary angiography and/or percutaneous coronary intervention * Coronary artery disease with at least 1 or more visually assessed de novo coronary stenosis (30-90% diameter stenosis) in native major epicardial vessel or its branches by coronary angiogram.

Exclusion criteria

* Contraindication to adenosine administration * Previous Coronary Artery Bypass surgery with patent grafts to the interrogated vessel

Design outcomes

Primary

MeasureTime frameDescription
QFR- iFR diagnostic grey zone calculation.1 hourQFR limits for achieving 95% sensitivity and specificity in comparison to iFR
Diagnostic performance of QFR in comparison to iFR1 hourreported as sensitivity, specificity, positive and negative likelihood ratio of QFR according to iFR

Secondary

MeasureTime frameDescription
Diagnostic performance of QFR in comparison to FFR1 hourreported as sensitivity, specificity, positive and negative likelihood ratio of QFR according to FFR
QFR- FFR diagnostic grey zone calculation.1 hourQFR limits for achieving 95% sensitivity and specificity in comparison to FFR
Diagnostic performance of iFR in comparison to FFR1 hourreported as sensitivity, specificity, positive and negative likelihood ratio of iFR according to FFR
effect of 3D QCA characteristics on QFR-iFR-FFR disagreement.1 hourInfluence of minimum luminal area (MLA), percentage area stenosis, lesion length, and minimum luminal diameter (MLD) and percentage diameter stenosis in the prediction of QFR-iFR-FFR disagreement.
Effect of lesion location on QFR-iFR-FFR disagreement.1 hourEvaluation of lesion location in the prediction of QFR-iFR-FFR disagreement.
iFR- FFR diagnostic grey zone calculation.1 houriFR limits for achieving 95% sensitivity and specificity in comparison to FFR
Effect of p20-DAC2 score in proximal and mid-LAD stenosis on QFR-iFR-FFR disagreement.1 hourEvaluation of p20-DAC2 score in proximal and mid-LAD stenosis in in the prediction of QFR-iFR-FFR disagreement.

Other

MeasureTime frameDescription
Cost analysis1 hourCost savings of removing the need for Adenosine by using iFR. Evaluation of costs by excess/reduced need for stenting when iFR and FFR disagree

Countries

Germany

Contacts

Primary ContactChristoph Jensen, MD, PHD
c.jensen@contilia.de0049-201-897-86222
Backup ContactPieter Ghijselinck, MD
p.ghijselinck@contilia.de0049-201-897-86273

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026